Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash-to-Debt 0.08
DHR's Cash-to-Debt is ranked lower than
95% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. DHR: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.13 Max: 0.95
Current: 0.08
0
0.95
Equity-to-Asset 0.59
DHR's Equity-to-Asset is ranked lower than
58% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DHR: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.51 Max: 0.65
Current: 0.59
0.38
0.65
Debt-to-Equity 0.35
DHR's Debt-to-Equity is ranked lower than
53% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. DHR: 0.35 )
Ranked among companies with meaningful Debt-to-Equity only.
DHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.15  Med: 0.36 Max: 0.75
Current: 0.35
0.15
0.75
Debt-to-EBITDA 2.05
DHR's Debt-to-EBITDA is ranked lower than
59% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. DHR: 2.05 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.76  Med: 1.6 Max: 3.13
Current: 2.05
0.76
3.13
Interest Coverage 21.63
DHR's Interest Coverage is ranked lower than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. DHR: 21.63 )
Ranked among companies with meaningful Interest Coverage only.
DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 19.11 Max: 27.96
Current: 21.63
12.58
27.96
Piotroski F-Score: 8
Altman Z-Score: 4.26
Beneish M-Score: -2.60
WACC vs ROIC
7.52%
7.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating Margin % 17.11
DHR's Operating Margin % is ranked higher than
85% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. DHR: 17.11 )
Ranked among companies with meaningful Operating Margin % only.
DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.68 Max: 17.23
Current: 17.11
13.79
17.23
Net Margin % 13.33
DHR's Net Margin % is ranked higher than
88% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. DHR: 13.33 )
Ranked among companies with meaningful Net Margin % only.
DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.54 Max: 16.33
Current: 13.33
10.3
16.33
ROE % 9.70
DHR's ROE % is ranked higher than
70% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. DHR: 9.70 )
Ranked among companies with meaningful ROE % only.
DHR' s ROE % Range Over the Past 10 Years
Min: 9.7  Med: 12.19 Max: 14.27
Current: 9.7
9.7
14.27
ROA % 5.58
DHR's ROA % is ranked higher than
75% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. DHR: 5.58 )
Ranked among companies with meaningful ROA % only.
DHR' s ROA % Range Over the Past 10 Years
Min: 5.42  Med: 7.43 Max: 8.58
Current: 5.58
5.42
8.58
ROC (Joel Greenblatt) % 84.36
DHR's ROC (Joel Greenblatt) % is ranked higher than
90% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. DHR: 84.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 67.18  Med: 86.99 Max: 124.73
Current: 84.36
67.18
124.73
3-Year Revenue Growth Rate -1.20
DHR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. DHR: -1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 9.7 Max: 36.1
Current: -1.2
-9.7
36.1
3-Year EBITDA Growth Rate 1.50
DHR's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 1.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.3  Med: 14.3 Max: 41.8
Current: 1.5
-10.3
41.8
3-Year EPS without NRI Growth Rate 14.80
DHR's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 14.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.2  Med: 14.8 Max: 92
Current: 14.8
-22.2
92
GuruFocus has detected 5 Warning Signs with Danaher Corp DHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DHR's 30-Y Financials

Financials (Next Earnings Date: 2019-04-19)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» DHR's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q1 2018

DHR Guru Trades in Q1 2018

Ron Baron 849 sh (New)
Jeremy Grantham 176,711 sh (New)
Paul Tudor Jones 2,459 sh (New)
Ken Fisher 5,768 sh (+3.74%)
Robert Olstein 55,000 sh (+1.85%)
Pioneer Investments 1,601,225 sh (+149.19%)
MS Global Franchise Fund 313,578 sh (+83.13%)
Vanguard Health Care Fund 3,798,100 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 291,350 sh (unchged)
Tom Russo Sold Out
John Griffin Sold Out
Wallace Weitz 239,761 sh (-0.05%)
Arnold Van Den Berg 97,535 sh (-1.43%)
Dodge & Cox 5,117,323 sh (-1.44%)
Joel Greenblatt 122,152 sh (-3.85%)
Daniel Loeb 3,250,000 sh (-1.81%)
Murray Stahl 20,443 sh (-4.86%)
Steven Cohen 225,900 sh (-19.64%)
Jim Simons 968,200 sh (-15.80%)
Louis Moore Bacon 14,534 sh (-89.35%)
Mario Gabelli 9,910 sh (-0.55%)
Signature Select Canadian Fund 44,716 sh (-33.67%)
» More
Q2 2018

DHR Guru Trades in Q2 2018

Caxton Associates 11,369 sh (New)
Ron Baron 970 sh (+14.25%)
Joel Greenblatt 231,053 sh (+89.15%)
Jeremy Grantham 227,732 sh (+28.87%)
Paul Tudor Jones 8,339 sh (+239.12%)
Pioneer Investments 1,827,454 sh (+14.13%)
Jim Simons 1,718,200 sh (+77.46%)
MS Global Franchise Fund 367,963 sh (+17.34%)
Vanguard Health Care Fund 3,798,100 sh (unchged)
Daniel Loeb 3,250,000 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 291,350 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 5,262 sh (-8.77%)
Wallace Weitz 239,637 sh (-0.05%)
Robert Olstein 51,000 sh (-7.27%)
Dodge & Cox 4,841,618 sh (-5.39%)
Murray Stahl 19,457 sh (-4.82%)
Steven Cohen 20,000 sh (-91.15%)
Mario Gabelli 9,270 sh (-6.46%)
Arnold Van Den Berg 97,305 sh (-0.24%)
» More
Q3 2018

DHR Guru Trades in Q3 2018

Jim Simons 3,219,500 sh (+87.38%)
Pioneer Investments 2,256,375 sh (+23.47%)
Ron Baron 1,051 sh (+8.35%)
Steven Cohen 268,700 sh (+1243.50%)
MS Global Franchise Fund 390,478 sh (+6.12%)
Vanguard Health Care Fund 3,798,100 sh (unchged)
Daniel Loeb 3,250,000 sh (unchged)
Jeremy Grantham 227,732 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
Ken Fisher 4,834 sh (-8.13%)
Eaton Vance Worldwide Health Sciences Fund 235,462 sh (-19.18%)
Mario Gabelli 9,200 sh (-0.76%)
Robert Olstein 50,000 sh (-1.96%)
Wallace Weitz 116,077 sh (-51.56%)
Murray Stahl 19,057 sh (-2.06%)
Joel Greenblatt 165,928 sh (-28.19%)
Caxton Associates 3,458 sh (-69.58%)
Paul Tudor Jones 3,137 sh (-62.38%)
Dodge & Cox 4,810,818 sh (-0.64%)
Signature Select Canadian Fund 27,916 sh (-37.57%)
Arnold Van Den Berg 97,117 sh (-0.19%)
» More
Q4 2018

DHR Guru Trades in Q4 2018

Vanguard Health Care Fund 4,250,200 sh (+11.90%)
Mario Gabelli 9,350 sh (+1.63%)
Wallace Weitz 171,200 sh (+47.49%)
Ron Baron 1,357 sh (+29.12%)
Pioneer Investments 2,678,959 sh (+18.73%)
Chuck Akre 1,655,300 sh (unchged)
Jim Simons Sold Out
Caxton Associates Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 4,225 sh (-12.60%)
Eaton Vance Worldwide Health Sciences Fund 210,279 sh (-10.70%)
Robert Olstein 27,000 sh (-46.00%)
Daniel Loeb 3,110,000 sh (-4.31%)
Jeremy Grantham 207,465 sh (-8.90%)
Murray Stahl 17,033 sh (-10.62%)
Dodge & Cox 4,690,968 sh (-2.49%)
Joel Greenblatt 52,028 sh (-68.64%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus category: |Basic |Premium Premium Tools | Premium Plus Premium Plus | Modify your Personalized List of Gurus
Guru Date Action
 Impact Price Range
(Average)*		 Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Danaher Corp

SymbolPriceYieldDescription
DHRpA.PFD1035.100.00PRF CONVERT 15/04/2022 USD - Ser A

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:TMO, XAMS:PHIA, NYSE:A, NYSE:IQV, TSE:6869, XSWX:LONN, NYSE:LH, NAS:IDXX, NYSE:DGX, XTER:SRT3, SZSE:300676, XPAR:BIM, XPAR:ERF, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NAS:ICLR, NAS:EXAS, XTER:AFX » details
Traded in other countries:DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK,
Headquarter Location:USA
Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

After the spin-off of Fortive in 2016, Danaher is a diversified and mostly healthcare-focused instrument and supplies manufacturer. After the spin, Danaher retains four main business segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Each segment represents approximately 31%, 32%, 15%, and 22% of revenue, respectively.

Guru Investment Theses on Danaher Corp

Keeley Funds Comments on Danaher Corp - Oct 24, 2017

Notable activity included continuing to build our initial position in DXC Technology and initiating a new, small position in Danaher Corp. Danaher (NYSE:DHR) has an outstanding track record of operational excellence through the application of Lean Manufacturing practices and culture, as well as astute acquirers. Recently the company has spun its industrial-focused assets into a separate entity, and the new Danaher is focused on life sciences, diagnostics, environmental and dental industries. We believe this “new” Danaher has the opportunity to continue compounding its business value for many years to come.

From Wallace Weitz (Trades, Portfolio)'s Partners III Fund third-quarter 2017 shareholder commentary.

Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Danaher Corp

Danaher Announces Quarterly Dividend
March 8, 2019
Read more...
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
March 1, 2019
Read more...
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
February 26, 2019
Read more...
Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock
February 25, 2019
Read more...
Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion
February 25, 2019
Read more...
Danaher To Present At Barclays Industrial Select Conference
February 13, 2019
Read more...
Danaher CEO To Comment On Financial Performance
January 7, 2019
Read more...
Danaher To Present At J.P. Morgan Healthcare Conference
January 2, 2019
Read more...
Danaher Schedules Fourth Quarter 2018 Earnings Conference Call
December 27, 2018
Read more...
Danaher Announces Quarterly Dividend
December 3, 2018
Read more...

Ratios

vs
industry		 vs
history
PE Ratio 34.22
DHR's PE Ratio is ranked higher than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. DHR: 34.22 )
Ranked among companies with meaningful PE Ratio only.
DHR' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 14.82 Max: 34.49
Current: 34.22
9.61
34.49
Forward PE Ratio 26.53
DHR's Forward PE Ratio is ranked lower than
53% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DHR: 26.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 34.22
DHR's PE Ratio without NRI is ranked higher than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. DHR: 34.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
DHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.66  Med: 15.89 Max: 38.03
Current: 34.22
9.66
38.03
Price-to-Owner-Earnings 27.08
DHR's Price-to-Owner-Earnings is ranked higher than
68% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. DHR: 27.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.59  Med: 11.64 Max: 27.67
Current: 27.08
7.59
27.67
PB Ratio 3.20
DHR's PB Ratio is ranked higher than
70% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. DHR: 3.20 )
Ranked among companies with meaningful PB Ratio only.
DHR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.87 Max: 3.21
Current: 3.2
1.19
3.21
PS Ratio 4.57
DHR's PS Ratio is ranked lower than
53% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. DHR: 4.57 )
Ranked among companies with meaningful PS Ratio only.
DHR' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.05 Max: 4.6
Current: 4.57
1.01
4.6
Price-to-Free-Cash-Flow 27.02
DHR's Price-to-Free-Cash-Flow is ranked higher than
59% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. DHR: 27.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.59  Med: 13.61 Max: 27.22
Current: 27.02
7.59
27.22
Price-to-Operating-Cash-Flow 22.60
DHR's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. DHR: 22.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.81  Med: 11.68 Max: 22.78
Current: 22.6
6.81
22.78
EV-to-EBIT 29.08
DHR's EV-to-EBIT is ranked lower than
55% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. DHR: 29.08 )
Ranked among companies with meaningful EV-to-EBIT only.
DHR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 12.4 Max: 29.29
Current: 29.08
8
29.29
EV-to-EBITDA 21.11
DHR's EV-to-EBITDA is ranked higher than
55% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. DHR: 21.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.2 Max: 21.25
Current: 21.11
6.7
21.25
EV-to-Revenue 5.05
DHR's EV-to-Revenue is ranked lower than
52% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. DHR: 5.05 )
Ranked among companies with meaningful EV-to-Revenue only.
DHR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.1 Max: 5.1
Current: 5.05
1.2
5.1
Shiller PE Ratio 35.06
DHR's Shiller PE Ratio is ranked higher than
77% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. DHR: 35.06 )
Ranked among companies with meaningful Shiller PE Ratio only.
DHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.32  Med: 22.83 Max: 35.35
Current: 35.06
15.32
35.35
Current Ratio 1.47
DHR's Current Ratio is ranked lower than
76% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. DHR: 1.47 )
Ranked among companies with meaningful Current Ratio only.
DHR' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.39 Max: 2.13
Current: 1.47
0.97
2.13
Quick Ratio 1.07
DHR's Quick Ratio is ranked lower than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DHR: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
DHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.99 Max: 1.74
Current: 1.07
0.61
1.74
Days Inventory 80.68
DHR's Days Inventory is ranked higher than
50% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. DHR: 80.68 )
Ranked among companies with meaningful Days Inventory only.
DHR' s Days Inventory Range Over the Past 10 Years
Min: 61.56  Med: 72.39 Max: 92
Current: 80.68
61.56
92
Days Sales Outstanding 64.03
DHR's Days Sales Outstanding is ranked lower than
53% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. DHR: 64.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
DHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.35  Med: 66.25 Max: 70.36
Current: 64.03
61.35
70.36
Days Payable 71.16
DHR's Days Payable is ranked higher than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. DHR: 71.16 )
Ranked among companies with meaningful Days Payable only.
DHR' s Days Payable Range Over the Past 10 Years
Min: 63.8  Med: 69.29 Max: 76.31
Current: 71.16
63.8
76.31

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield % 0.50
DHR's Dividend Yield % is ranked lower than
67% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. DHR: 0.50 )
Ranked among companies with meaningful Dividend Yield % only.
DHR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.17  Med: 0.28 Max: 0.84
Current: 0.5
0.17
0.84
Dividend Payout Ratio 0.17
DHR's Dividend Payout Ratio is ranked higher than
80% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. DHR: 0.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DHR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.1 Max: 0.22
Current: 0.17
0.03
0.22
3-Year Dividend Growth Rate 5.80
DHR's 3-Year Dividend Growth Rate is ranked higher than
61% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. DHR: 5.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DHR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 78.6
Current: 5.8
0
78.6
Forward Dividend Yield % 0.53
DHR's Forward Dividend Yield % is ranked lower than
66% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. DHR: 0.53 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.19
DHR's 5-Year Yield-on-Cost % is ranked higher than
92% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. DHR: 2.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.68
Current: 2.19
0.75
3.68
3-Year Average Share Buyback Ratio -0.70
DHR's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. DHR: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: -1.2 Max: 0.4
Current: -0.7
-7
0.4

Valuation & Return

vs
industry		 vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.75
DHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DHR: 1.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.14 Max: 2.85
Current: 1.75
0.55
2.85
Price-to-Median-PS-Value 2.23
DHR's Price-to-Median-PS-Value is ranked lower than
85% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DHR: 2.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 0.85 Max: 2.25
Current: 2.23
0.18
2.25
Earnings Yield (Greenblatt) % 3.42
DHR's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. DHR: 3.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 8.1 Max: 12.6
Current: 3.42
3.4
12.6
Forward Rate of Return (Yacktman) % 3.14
DHR's Forward Rate of Return (Yacktman) % is ranked lower than
69% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. DHR: 3.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 16.9 Max: 27.7
Current: 3.14
3.1
27.7

More Statistics

Revenue (TTM) (Mil) $19,893.00
EPS (TTM) $ 3.74
Beta0.93
Volatility22.29%
52-Week Range $94.59 - 129.42
Shares Outstanding (Mil)713.98

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 20,573 22,548 24,057
EBIT (Mil $) 4,177 4,878 5,610
EBITDA (Mil $) 5,039 5,779 6,295
EPS ($) 4.31 4.86 5.46
EPS without NRI ($) 4.31 4.86 5.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 10.31%
Dividends per Share ($) 0.65 0.68 0.71

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

» More Articles for DHR

Headlines

Articles On GuruFocus.com
Danaher Announces Quarterly Dividend Mar 08 2019 
Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioC Mar 06 2019 
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offerin Mar 01 2019 
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offerin Feb 26 2019 
Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock Feb 25 2019 
Wall Street Pushes Higher Monday Feb 25 2019 
Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion Feb 25 2019 
Danaher To Present At Barclays Industrial Select Conference Feb 13 2019 
3 Stocks Move Tuesday Jan 29 2019 
Danaher CEO To Comment On Financial Performance Jan 07 2019 

More From Our Partners
Danaher to Gain From Solid Demand in Key Markets Amid Risks Mar 18 2019 - ZACKS

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}